Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
WAT 
Waters Corporation (WAT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: WAT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
22 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $355.74
1 Year Target Price $355.74
| 6 | Strong Buy |
| 1 | Buy |
| 15 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -8.38% | Avg. Invested days 37 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 20.81B USD | Price to earnings Ratio 31.55 | 1Y Target Price 355.74 |
Price to earnings Ratio 31.55 | 1Y Target Price 355.74 | ||
Volume (30-day avg) 22 | Beta 1.04 | 52 Weeks Range 275.05 - 423.56 | Updated Date 11/2/2025 |
52 Weeks Range 275.05 - 423.56 | Updated Date 11/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 11.08 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-04 | When Before Market | Estimate 3.21 | Actual - |
Profitability
Profit Margin 21.71% | Operating Margin (TTM) 26.22% |
Management Effectiveness
Return on Assets (TTM) 11.7% | Return on Equity (TTM) 37.03% |
Valuation
Trailing PE 31.55 | Forward PE 22.62 | Enterprise Value 20333160929 | Price to Sales(TTM) 6.83 |
Enterprise Value 20333160929 | Price to Sales(TTM) 6.83 | ||
Enterprise Value to Revenue 6.68 | Enterprise Value to EBITDA 19.23 | Shares Outstanding 59524130 | Shares Floating 59402106 |
Shares Outstanding 59524130 | Shares Floating 59402106 | ||
Percent Insiders 0.16 | Percent Institutions 100 |
Upturn AI SWOT
Waters Corporation
Company Overview
History and Background
Waters Corporation was founded in 1958 by James Logan Waters. Initially focused on liquid chromatography, the company has evolved into a leading provider of analytical instruments and software systems. Key milestones include the development of breakthrough LC technologies and expansion into mass spectrometry.
Core Business Areas
- Waters Division: Focuses on liquid chromatography (LC) and related technologies, providing instruments, columns, and consumables for separation, purification, and analysis of chemical compounds.
- TA Instruments Division: Develops and manufactures thermal analysis, rheology, and microcalorimetry instruments used to characterize the physical and mechanical properties of materials.
Leadership and Structure
Udit Batra serves as the President and CEO. The company operates with a divisional structure, with Waters Division and TA Instruments operating as separate business units. Board of Directors include independent directors.
Top Products and Market Share
Key Offerings
- ACQUITY UPLC Systems: Ultra-Performance Liquid Chromatography systems offering high resolution and sensitivity. Competitors include Agilent (A) and Thermo Fisher Scientific (TMO). Revenue is significant, but exact figures are proprietary. High market share in pharmaceutical research.
- Xevo Mass Spectrometry Systems: Mass spectrometry instruments used for identifying and quantifying chemical compounds. Competitors are Agilent (A), Bruker (BRKR) and Thermo Fisher Scientific (TMO). Revenue is significant, but exact figures are proprietary. Significant market share in environmental testing.
- TA Instruments Thermal Analyzers: DSC, DMA, TGA instruments for material characterization. Competitors are PerkinElmer (PKI) and NETZSCH Group. Revenue is significant, but exact figures are proprietary.
Market Dynamics
Industry Overview
The analytical instruments industry is driven by advancements in science, increasing regulations, and growing demand for testing in pharmaceuticals, food safety, environmental monitoring, and materials science. It is a highly competitive and innovative space.
Positioning
Waters Corporation holds a leading position in liquid chromatography and mass spectrometry. Its competitive advantage stems from its technology innovation, brand reputation, and global service network.
Total Addressable Market (TAM)
The estimated TAM for analytical and life science instrumentation is approximately $70 billion. Waters is positioned to capture a significant portion of this market through its advanced technology and global reach.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Innovative technology portfolio
- Global service and support network
- Leading position in LC and MS
Weaknesses
- Dependence on pharmaceutical industry
- Potential for product obsolescence
- High R&D expenses
- TA Instruments lagging Waters Division in Growth
Opportunities
- Expanding into emerging markets
- Developing new applications for existing technologies
- Acquiring complementary businesses
- Growth in biopharmaceuticals
Threats
- Intense competition
- Economic downturns
- Technological disruptions
- Regulatory changes
Competitors and Market Share
Key Competitors
- A
- TMO
- BRKR
- PKI
Competitive Landscape
Waters excels in liquid chromatography and mass spectrometry, but faces strong competition from Agilent and Thermo Fisher Scientific. Waters differentiates itself through its specialized solutions and customer service.
Major Acquisitions
Andrew Alliance
- Year: 2020
- Acquisition Price (USD millions): 136
- Strategic Rationale: Expanded Waters' automation and sample preparation capabilities, enhancing its offerings for high-throughput workflows.
Growth Trajectory and Initiatives
Historical Growth: Financial data cannot be provided as I don't have real time information.
Future Projections: Financial data cannot be provided as I don't have real time information.
Recent Initiatives: Waters has focused on expanding its product portfolio through acquisitions and internal development, targeting growth in key applications such as biopharmaceutical analysis and food safety. They have also invested in digital solutions and services.
Summary
Waters Corporation is a strong player in the analytical instrument market, with a solid presence in liquid chromatography and mass spectrometry. Its innovation and customer service are working well, but the company faces challenges from competitors and dependence on the pharmaceutical industry. It must capitalize on emerging markets and new applications to maintain its growth trajectory and beware of the technological disruptors.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Analyst estimates
- Publicly available information
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is based on estimates and may vary. Financial data is not real-time.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Waters Corporation
Exchange NYSE | Headquaters Milford, MA, United States | ||
IPO Launch date 1995-11-16 | President, CEO & Director Dr. Udit Batra Ph.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 7600 | Website https://www.waters.com |
Full time employees 7600 | Website https://www.waters.com | ||
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Further, the company provides thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.